130.98
price up icon2.45%   3.13
after-market Handel nachbörslich: 130.59 -0.39 -0.30%
loading
Schlusskurs vom Vortag:
$127.85
Offen:
$130.56
24-Stunden-Volumen:
586.67K
Relative Volume:
0.41
Marktkapitalisierung:
$19.19B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
12.93
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
+1.96%
1M Leistung:
+4.99%
6M Leistung:
-8.83%
1J Leistung:
-41.60%
1-Tages-Spanne:
Value
$129.98
$131.25
1-Wochen-Bereich:
Value
$121.05
$131.25
52-Wochen-Spanne:
Value
$110.03
$236.48

Biogen Inc Stock (BIIB) Company Profile

Name
Firmenname
Biogen Inc
Name
Telefon
(781) 464-2000
Name
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
7,605
Name
Twitter
@biogen
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
BIIB's Discussions on Twitter

Vergleichen Sie BIIB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BIIB
Biogen Inc
130.98 18.73B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
798.89 697.04B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
169.10 404.05B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.55 330.51B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.97 226.17B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
70.03 296.73B 43.59B 15.04B 10.74B 3.3766

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-21 Fortgesetzt Truist Hold
2025-04-28 Herabstufung HSBC Securities Buy → Hold
2025-04-04 Herabstufung Argus Buy → Hold
2025-02-11 Eingeleitet Bernstein Mkt Perform
2025-01-02 Herabstufung Piper Sandler Overweight → Neutral
2024-12-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-12-16 Herabstufung Stifel Buy → Hold
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-09 Herabstufung Jefferies Buy → Hold
2024-11-18 Herabstufung Needham Buy → Hold
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-14 Eingeleitet Citigroup Neutral
2024-10-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-02-14 Bestätigt Needham Buy
2024-02-14 Herabstufung Wells Fargo Overweight → Equal Weight
2024-01-24 Herabstufung UBS Buy → Neutral
2023-12-20 Fortgesetzt Cantor Fitzgerald Overweight
2023-12-07 Hochstufung Raymond James Mkt Perform → Outperform
2023-09-06 Eingeleitet HSBC Securities Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-07-24 Bestätigt UBS Buy
2023-05-01 Hochstufung Guggenheim Neutral → Buy
2023-04-17 Hochstufung Piper Sandler Neutral → Overweight
2022-10-26 Hochstufung Goldman Neutral → Buy
2022-10-13 Hochstufung Stifel Hold → Buy
2022-10-07 Hochstufung Argus Hold → Buy
2022-09-28 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-09-28 Hochstufung Mizuho Neutral → Buy
2022-09-28 Hochstufung Robert W. Baird Neutral → Outperform
2022-04-18 Hochstufung Wells Fargo Equal Weight → Overweight
2022-03-08 Herabstufung Stifel Buy → Hold
2022-03-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-04 Bestätigt Barclays Equal Weight
2022-02-04 Bestätigt BofA Securities Neutral
2022-02-04 Bestätigt Cowen Outperform
2022-02-04 Bestätigt Morgan Stanley Overweight
2022-02-04 Bestätigt Needham Buy
2022-02-04 Bestätigt Oppenheimer Outperform
2022-02-04 Bestätigt RBC Capital Mkts Sector Perform
2022-02-04 Bestätigt Robert W. Baird Neutral
2022-02-04 Bestätigt Wedbush Neutral
2022-02-04 Bestätigt Wells Fargo Equal Weight
2022-02-04 Bestätigt Wolfe Research Peer Perform
2022-01-13 Herabstufung Guggenheim Buy → Neutral
2022-01-12 Herabstufung Piper Sandler Overweight → Neutral
2021-12-10 Fortgesetzt Raymond James Mkt Perform
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-09-23 Eingeleitet Needham Buy
2021-06-18 Hochstufung Piper Sandler Neutral → Overweight
2021-06-14 Bestätigt Truist Buy
2021-06-11 Hochstufung Bernstein Mkt Perform → Outperform
2021-06-10 Hochstufung UBS Neutral → Buy
2021-06-08 Hochstufung Atlantic Equities Underweight → Neutral
2021-06-08 Bestätigt Barclays Equal Weight
2021-06-08 Hochstufung Citigroup Sell → Neutral
2021-06-08 Bestätigt H.C. Wainwright Buy
2021-06-08 Bestätigt Jefferies Buy
2021-06-08 Bestätigt Morgan Stanley Overweight
2021-06-08 Bestätigt RBC Capital Mkts Sector Perform
2021-06-08 Hochstufung Robert W. Baird Underperform → Neutral
2021-06-08 Bestätigt Stifel Buy
2021-06-08 Hochstufung William Blair Mkt Perform → Outperform
2021-06-07 Hochstufung BofA Securities Underperform → Neutral
2021-06-07 Hochstufung Cowen Market Perform → Outperform
2021-06-07 Hochstufung Raymond James Underperform → Mkt Perform
2021-02-05 Herabstufung DZ Bank Buy → Hold
2021-01-29 Hochstufung Stifel Hold → Buy
2020-11-10 Hochstufung DZ Bank Hold → Buy
2020-11-09 Herabstufung Atlantic Equities Neutral → Underweight
2020-11-09 Herabstufung BofA Securities Neutral → Underperform
2020-11-09 Herabstufung Cowen Outperform → Market Perform
2020-11-09 Bestätigt H.C. Wainwright Buy
2020-11-04 Hochstufung BofA Securities Underperform → Neutral
2020-11-04 Hochstufung Jefferies Hold → Buy
2020-11-04 Hochstufung Wells Fargo Equal Weight → Overweight
2020-10-28 Eingeleitet UBS Neutral
2020-07-27 Hochstufung Morgan Stanley Underweight → Overweight
2020-06-22 Herabstufung Barclays Overweight → Equal Weight
2020-06-22 Bestätigt RBC Capital Mkts Sector Perform
2020-06-09 Herabstufung Bernstein Outperform → Mkt Perform
2020-04-23 Herabstufung Citigroup Neutral → Sell
2020-04-23 Herabstufung Raymond James Mkt Perform → Underperform
2020-03-31 Eingeleitet Wolfe Research Peer Perform
2020-02-27 Eingeleitet Barclays Overweight
2020-01-27 Hochstufung Canaccord Genuity Hold → Buy
2019-12-13 Hochstufung Credit Suisse Underperform → Neutral
2019-12-02 Herabstufung Robert W. Baird Neutral → Underperform
Alle ansehen

Biogen Inc Aktie (BIIB) Neueste Nachrichten

pulisher
Jul 23, 2025

Biogen Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen to invest $2 billion in RTP, open new factory in 2025 - WRAL.com

Jul 23, 2025
pulisher
Jul 23, 2025

(BIIB) On The My Stocks Page - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen (NASDAQ:BIIB) Shares Acquired Rep. Robert Bresnahan, Jr. - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

How the Recombinant Dna Technology Market Will Evolve by 2032 - openPR.com

Jul 23, 2025
pulisher
Jul 23, 2025

KLP Kapitalforvaltning AS Has $21.36 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Envestnet Asset Management Inc. Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen Inc. (NASDAQ:BIIB) Stake Raised by Victory Capital Management Inc. - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Will Major North Carolina Expansion Change Biogen's (BIIB) Narrative? - simplywall.st

Jul 23, 2025
pulisher
Jul 22, 2025

Beacon Investment Advisory Services Inc. Sells 3,529 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Benzinga

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen, one of the largest employers in RTP, plans $2B investment in the Triangle - Axios

Jul 22, 2025
pulisher
Jul 22, 2025

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Allianz Asset Management GmbH Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

Los Angeles Capital Management LLC Takes $5.93 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

Spinal Muscular Atrophy Treatment Market Growth Accelerated - openPR.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Biogen Inc. a good long term investmentExplosive wealth accumulation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Biogen Inc. stock pricePowerful growth strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen: Hold Rating Amid Stagnant Growth and Uncertain Prospects - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen to invest further $2bn in North Carolina’s Research Triangle Park - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics shares rise 2.41% premarket after Biogen's $2 billion investment in North Carolina manufacturing. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Biogen Inc. stockFree Predictions - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Biogen investing $2B to expand operations in RTP - ABC11

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - yahoo.co

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - Biogen

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Inc. - Via Ritzau

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest $2 billion in RTP facility - CBS 17

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Inc. Invests $2B In North Carolina Expansion - Business Facilities

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Inc. Announces $2 Billion Expansion in North Carolina's Research Triangle Park Amid U.S. Manufacturing Push - Hoodline

Jul 21, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Bets Big On $2 Billion Expansion To Boost US Drug ManufacturingBiogen (NASDAQ:BIIB) - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen invests $2B in U.S. manufacturing — but not in Massachusetts - The Business Journals

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest $2 billion in Research Triangle Park facilities - CBS 17

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen’s Pediatric RRMS Study Completion: Market Implications and Insights - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen (NASDAQ:BIIB) Coverage Initiated by Analysts at Truist Financial - MarketBeat

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Invests $20 Billion in North Carolina to Counter 200% Tariff Threat - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest further $2 billion in North Carolina facilities - The Pharma Letter

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm - Reuters

Jul 21, 2025
pulisher
Jul 21, 2025

Drugmaker Biogen to invest $2 billion more in North Carolina - 104.1 WIKY

Jul 21, 2025
pulisher
Jul 21, 2025

Truist downgrades Biogen, citing growth challenges, limited pipeline upside - TradingView

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Announces Additional Investment In North Carolina's RTP - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen (BIIB) Increases Investment in North Carolina Manufacturi - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest $2 billion more in North Carolina By Reuters - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary | BIIB Stock News - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest $2 billion in North Carolina manufacturing expansion By Investing.com - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Announces $2 Billion Investment to Expand Manufacturing in North Carolina's Research Triangle Park - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest $2 billion more in North Carolina - Reuters

Jul 21, 2025

Finanzdaten der Biogen Inc-Aktie (BIIB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general SNY
$50.16
price up icon 2.89%
$113.56
price up icon 3.08%
drug_manufacturers_general PFE
$25.36
price up icon 0.88%
$309.22
price up icon 1.15%
drug_manufacturers_general MRK
$83.98
price up icon 2.90%
drug_manufacturers_general NVO
$70.03
price up icon 4.87%
Kapitalisierung:     |  Volumen (24h):